Table 1.
Baseline characteristics at starting dialysis among diabetic kidney patients undergoing hemodialysis and peritoneal dialysis.
| Before Propensity Score Weighting | After Propensity Score Weighting | |||||
|---|---|---|---|---|---|---|
| HD | PD | ASMD | HD | PD | ASMD | |
| (n = 42,563) | (n = 4216) | (n = 42,563) | (n = 4216) | |||
| Age (years) | 65.83 ± 11.55 | 60.38 ± 12.89 | 0.4452 | 60.45 ± 3.96 | 60.38 ± 12.89 | 0.0072 |
| Male | 49.25% | 50.62% | 0.0274 | 50.76% | 50.62% | 0.0029 |
| Stroke | 43.93% | 33.37% | 0.2181 | 33.53% | 33.37% | 0.0032 |
| CAD | 57.63% | 48.58% | 0.1821 | 51.26% | 48.58% | 0.0033 |
| CHF | 61.32% | 49.95% | 0.2302 | 50.11% | 49.95% | 0.0032 |
| Hyperlipidemia | 73.73% | 75.88% | 0.0494 | 75.85% | 75.88% | 0.0006 |
| AF | 7.77% | 6.95% | 0.0314 | 6.98% | 6.95% | 0.0012 |
| Hypertension | 96.97% | 95.66% | 0.0696 | 95.69% | 95.66% | 0.0014 |
| LC | 17.57% | 14.54% | 0.0826 | 14.56% | 14.54% | 0.0006 |
| Use of sulfonylurea | 62.86% | 55.03% | 0.1598 | 55.27% | 55.03% | 0.0048 |
| Use of TZD | 21.45% | 22.06% | 0.0147 | 22.19% | 22.06% | 0.0031 |
| Use of glinide | 40.91% | 38.14% | 0.0567 | 38.32% | 38.14% | 0.0037 |
| Use of DPP4 | 5.52% | 6.19% | 0.0287 | 6.2% | 6.19% | 0.0004 |
| Use of acarbose | 27.79% | 27.35% | 0.0099 | 27.53% | 27.35% | 0.0042 |
| Use of insulin | 73.9% | 68.15% | 0.1272 | 68.29% | 68.15% | 0.0031 |
HD, hemodialysis; PD, peritoneal dialysis; ASMD, absolute standardized mean difference; CAD, coronary artery disease; CHF, congestive heart failure; AF, atrial fibrillation; LC, liver cirrhosis; TZD, thiazolidinediones; DPP4, dipeptidyl peptidase 4 inhibitors.